1Van der Burgh MEL, Lammes FB, van Putten WLJ et al. The prognostic value of the serum half- time of CA125 during the induction of chemotherapy. Gynecol Oncol, 2003, 30 (6): 307.
2Markowska J, Wilkoszarska J, Emerich J et al. Factors influencing period of time between negative second - look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland. Eur J Gynaecol Oncol,2004, 21: 164 ～ 167.
3Geiser JP, Miller GA, Lee TH et al. Relationship of preoperative serum CA125 to survival in epithelial ovarian carcinoma. J Reprod Med,2002, 41: 140 ～ 142.
4Hogdall CK, Hording U, Norgaard - Pedersen B et al. Serum tetranectin and CA125 used to monitor the course of treatment in ovarian cancer patients. Eur J Obstet Gynecol Reprod Biol, 2003, 57: 175 ～ 178.
5Low RN, Saleh F, Song S et al. Treated ovarian cancer: comparison of MR imaging with serum CA125 level and physical examination - a longitudinal study. Radiology, 2001,211: 519 ～528.
6Kurokawa T, Yoshida Y, Kawahara K. Whole - body PET with FDG is useful for following up an ovarian cancer patient with only rising CA125levels within the normal range. Ann Nucl Med, 2002, 16 (7): 491 ～493.
7Wilder JL, PavlikE , Straughan JI et al. Clinical implications of a rising serum CA125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol, 2003, 89 (2):233 ～ 235.
8Fioretti P,Lavin PT,Gallion HH,et al.The concomitant determintion of different serum tumor markers in epithelial ovarian cancer:Relevance for monitoring the response to chemotherapy and follow up of patients[J].Gynecol Oncol,1992,44(1):155-162
9Jeyarajah AR,Ind TE,Skates S,et al.Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal[J].Women Cancer,1999,85(9):2068-2072
10Evaluation of the diagnostic usefulness of CA125 immunoscintigraphy for ovarian carcinoma follow-up after treatment:contribution of this technique in Grenoble University Medical Center[J].Bull Cancer,1997,84(11):1033-1042
